Er-Positive Pr-Positive, Her2-Negative Breast Cancer Treatment (2023)

1. Types of Breast Cancer: Triple Negative, ER-Positive, HER2-Positive

  • Mar 19, 2023 · Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. You may have hormone ...

  • Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.

Types of Breast Cancer: Triple Negative, ER-Positive, HER2-Positive

2. Hormone Receptor Status and HER2 Status | Susan G. Komen®

  • Estrogen receptor status and progesterone receptor status. Breast cancers that are ER-positive tend to be PR-positive. And cancers that are ER-negative tend to ...

  • Hormone receptor status and HER2 status are the main factors in planning breast cancer treatment.

Hormone Receptor Status and HER2 Status | Susan G. Komen®

3. Breast Cancer Hormone Receptor Status - American Cancer Society

  • See Triple-negative Breast Cancer to learn more. Triple-positive cancers are ER-positive, PR-positive, and HER2-positive. These cancers can be treated with ...

  • ‹ ì}ێÜH–Øû~EL6Ü*y‹•u¿H*µK¥ÒÅ-uרª%·!’ŒÌ“‘â%KÙÓÌÂ,`øÍØ]Ø_ÆØ]kÌ6°;ÆÚíè~ëyë56`Øÿàs‚—d0L2“UJjªV1Éä9'Nœ8·ˆ¸÷#K˜þxÈHßØ÷ïþ!6uz‡-æ´îÿ¹×gԂ¿äހù”˜}êzÌ?l}qþÈØo¥Çg<ðÙ;¿¯¹› ~`áþÐ`o>:l‡àÆ9|;õ–4È;# †)CêóŽÍZ“O<=9<±zév°Ã–-¨Õn÷™1b.ïrš'ÕúuØÎç¾Íî?põ|rL“¹ä‰pÂaä3ÙÐ.9ó©xäkrâù®è1gòˆÀÝ£|¤NÜþL˜œùã{íðåäޏƒ ©V`ú è‘3ÓåC_ëú†!ñðÂ[žk¶Úmjzk¦å£­5sÒ®ðȸ¼<þì՗||þ¶=ÚjÓryû×îÝÞÉÖ½~ܶ|Ã{þôÇOŸ}õãÑ»çöúÎÙËÇÇg§Oß¾yhٟûÖ'Ðꂍá!¾ºô|úöìÁ+~f=9{÷OŽ-‚Buæ:¢!–­û÷Úᕞ¶Ç" ix‰ÿ¨K†€ó)õû䐴ڦdZ¿äµ;²#Œè^àXÌõ|êXÜéÔPž§=Gx<ÓÊè‡Ýg¸Qžì¾5”ÆÖÝÜ{.:Üf€ÆÊ-˜}ûäá!€µkñʼnÍðùøcÒ@Ã6_ó™ç¯8tÄ{>´xÌ=Âî¸}[ýÎ9Ñõá;í_^~͇ÔúzhÓqGˆ‹¯=n_Üþzu·V>ùÑÚ?Ä/ܾ]ôô'àNüBBÔ'¤^µÈ²’à ·Ã+¼Ýzȼ_[ÉË.¹c‰Ë5‹úôƒ0Nßúúkò“ŸÆ ’ÛkÃÀë¯ü,ºMd'¿Æ§wˆØvtÿç·g6d# p“/ÀÁüZv ³Z« ŒÃH³^ÇÀ§ Lžp8ªàV‚Jë™| àX¦:ð¤udÛä¨#‚X÷ü»Ñ˜F åɊ®w¾H‹)¡DÕ&c1%8… `ŠÀñÝ1~ý‹3õªß Çg „•g¨èðþÜzK}]ÄéHGÞIÆçšË@DM¶Ò Ï*iµnO·ÕܯÔÊe6àÍ^ƒjöÂ/¶T„Pq¿Ž‰‡õhô ™¾þÑÓMÍãhÔÀÓèJA„ ]f1÷à…`ffÂ· Ÿ €TŸµ’v?ÏÈy¢)3“¼RÞW'¥Oq‰2ä÷aqŸÅzŒ€€‘!Þó|æbG'OB GD—ŒEà’P’q …룂@ÅÆL.%Õ0_ª4!ñÖ@>` „– sٙš\Š'H—áOö5#Î.¥Ôk.¹å÷-6â&3äUÀ–ûÞãÁËØáÆÚú*ñú.w._]î:b• F”¨ÖÇÌ[%úŽ‚AÔnsm} D“úè‘H€Ò¦‹Í†}à/¼}ª+:Â÷RРٻ)°”b™€þäg¿ „WšáåðOVó„wWÃ?k+ÀhywÚíËË˵É؈æQ9äB¸Ÿ¯j¿—Vjó+œ³Ë}QÑT‹~RðË!PVI׋[Y&MÃOSÒÃ}È\|ؽ;€MJš®—*æ”SÉþ®óÏSšðL6%>o[t1ÇÀÛò ^Û=᡽ÿ¿Æ_¯»µ¡Ó›Ö|—ܽ{Ǥ®•úªfp8N4)ð”šÍtM®‚{ê$ñWÌ:Ô4ÌPö!NàÂÁù œ?—u—It'HRãș ‘LœßeFy0”·3(Âí¥AÑóÇ6óúݍË6óÍ5Óæ W6ï„ò“ú™\°×lÓ8 ËìZÎÎÆÆ.ÛÝÙ5Íí͝mz°·et¬Ã6×ÜY3=OñWñwäŸ~î°s7À!Îg:¬Ú=Ÿ ¬ "ý&™ðä8æ1‡Á5__eÓKÉä*6w¼¶ðÏ~z杵7žÎ‹ÎFQ¤GdXb@¹c„0ÐÇ]ßÞ°˜a²]c»³¿eì[c}›v7Ù~gפVÊOa¬qÝSn7p¤íC>ú8D_¹t*vå6ù™´c3^þ,.20O§y¶},D|ÒsÚ#Ï©êÃÍDVbdV.W­UoÕ^å·vùû§‡øÏ×_ƒÃ‰‘¯x«çÖBWýŽÃ.ÉC`úÊíµóÏù ®VC·P‚½ñn1ŽNr÷ÐBÈ÷ŒÏ@/®x·²þÓÕ7ðØD“˜EpÕ²íÞJœÕ[ŸÜúØ>¼õûö[·î¾Y£ÞØ1}7`ðeäVZQô$Õ>í Bše 'ÄénÁ[øï[öÝîڐºð¹Ï„ÅÖ8°Ôõ0`$[y³Ú½}÷ç·WB|5D¬Þ ™vk5…×ê­ÇçύÍºuz|ëöÝLßa8Fß©"D¹0r¶;ìSó³/×öæèÁø =~{ sã™ÛÝ}²+Þ{/¿üòÕÑþù§­éØVfø§.{.sŸµß¼ ˜;Æ¡¿·¿½¹p°¾¹½¹qÐ1;Vg‡ímšÛ»û{락dèÃËe¿øÜöðƒl¯ÓÝÚ^§[;[lw{ËÚ8ØïlîXëæ¾išl{¯®†$Æ?ñË;ðµÍmsßêÒÝî6ÝÚÜÚêìnÁ§7­ý½¹¾Ü áe÷¥‘˜ð׺u°cîmo˜l¸½~°Ë6ww7ØÆöÁÆú\Õ*ôÄOD¡µeäpèlï[Û»`óÝZß>ØÜììnïnvv¶è65÷˜‡Z&)ç‚îbŽ JM²î¾iìw××;›ëÛì`}ýà`Ÿ™]È J¹3N­¨!6»ÛëÛ»ë{›×ói¿úÏkË?@Å='‡H‡íRº³Gé.ÝÛÛÚÚ߄ë sŸYë;l^†j@>™qµíõ­½u‹n±ƒ­õ-ÖÙÞØÛïn‚¾üÛ fÔÀÈñMðǹ)°´=Ü¥#l·ÿLÙlÃ!¨Wj6zwŽ¾/$L¶k#Ђ¸×ŽR?÷:ÂÓ¦žw(ã~,4nÊ+hgH³Åf]ߥlR˜ß$”±}Àv6w;]«âkñQüs04dñµwÃZZ>š0Øi 0©IüH¢€Oà/ïçÀ‰/ޏç¯{m*Ñhzãd_©jnÇsd|CP÷xׅéRµ µ3¾ÚÆ8åOæh@šñ^æÓõ c_x%ÇÄaËâ&î€UÆÇ;ÜæþøNŸ[fäîµCBRÜ 'ûišR]1µ t˜eܐ?ÃN”÷^r‹‰çáM•6í ÈàC"Ÿ’S1† ´#cb‡-c#±†ÑvRhN}½ ÁÈ>~œˆEh¿N ”‘áÂcXÔ |ŒÛp<„?Z‰HÙÂcr˜:ÀnCގ qî xò~•ìc ìö†ÔÉ£ñ›?¹ žH;ütŒ¸”;8Ä=ý8Ät,p)XØ;$t£kܚ˜öÙ!&¿~µ&á§BùInH-év ;¸Cvv×6wþAê)¼U"&דËäjr‘ÂÉŸ`ºË‚'ÁG¬çÆdHp”¾ ‘û»­­ÍíîF+MÜä=aÔ~Z€(áÍ$¾0ŒÍԋui`ûònž|±wàÁÄc2`YOÆËãÆÇÂNæ§òFµ7åxšzfÒÊ(3Òr>œۈ¤?#*ÿöºÖö3×7‹ø‡¢Ôâ)OQ‘'—û2´OmðSÒ@iÉt€éeñ#aEö¾@ñëPÇQŸ+oa'¸—àª*Ð*’º‘1óÅP6Nȳ™‡×tЖ+†àÌ_:SP Xø.–ű*žy¸¦º–ÚhwƒA9ð_pÇÀ] ¶y/°ÑE¦FÏ $"}ðb[Î5 Æh4ÉNb wF˜«^¿}73%8=›{ýXõSÜ0/DŠ1þ¤ ‹Û@!‡à*JC‡m@À)Ì bfOôìýè͉fÕ ¤ƒ‰%YŸ§šCrB+ ËAU†‹okî¦:!ʪåum`+=d ÐAn÷Ú<‚‚Æ„NýòûÅ=3y'ö~kÂC Œ°yÞw†÷O€Áßü•°ïµ‡ó Ò{2Ž:ò¡ˆ@/ÃÐqD«y\æ`êïNjÍ"ðNžy>µð=‰9†AH´à® "§)÷0‰ðÍ¿éq‡‘_‚:ÍN×cÖÒk¦˜Ç§y¤3&±V™—×íÜ 3šÈS0‚øn®¿{¬2Sƒ÷‘|HV¾ÿ³ßþò·¿üþ7ßÿÁËïÿæû¿úþÏûÏ¿ÿ‹Ûñ«†f4•Ç4(‡OÉÊÿþ¿øû¿ý—ÿ×ù¿þø¯­.ªÙ×`õH>$+\ê|óg”{ׁQŸbNü—ÁÛ4˜= È±"+ŸºlüÍ²Éј{cæ\žàpzøŒ¬üð«?ýáWÿí‡_ýù¿ú#yñëþý/®·á2êhûT>$+ÿïþôÿü—¿ü¿üŸ¯£¡@µ¬S,ò!Yyó?þÕWã°à_V®ôý¸

4. Hormone Therapy for Breast Cancer - American Cancer Society

  • Jan 31, 2023 · Elacestrant (Orserdu). This drug can be used to treat advanced, ER-positive, HER2-negative breast cancer when the cancer cells have an ESR1 gene ...

  • Some breast cancers grow in response to hormones like estrogen. Hormone therapy blocks these hormones, which keeps the cancer from growing. Learn more here.

Hormone Therapy for Breast Cancer - American Cancer Society

5. New Drug Could Change Treatment Landscape for ER-Positive, HER2 ...

  • Dec 8, 2022 · ... ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

  • Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

New Drug Could Change Treatment Landscape for ER-Positive, HER2 ...

6. Endocrine therapy for ER-positive/HER2-negative ...

  • Treatment strategies have included decreasing estrogen synthesis and modulating or degrading the ER. However, ER+ breast cancer once diagnosed in the advanced ...

  • The estrogen receptor (ER) has been targeted for breast cancer treatment for over a century, but many challenges persist. ER-positivity identifies the largest breast cancer subgroup, and ER-directed therapies prolong survival and improve symptoms in the advanced setting with a very favorable side effect profile. Treatment strategies have included decreasing estrogen synthesis and modulating or degrading the ER. However, ER+ breast cancer once diagnosed in the advanced setting still represents an incurable condition. Many efforts are ongoing to circumvent resistance mechanisms with a few strategies already incorporated into clinical practice such as the combination of endocrine agents with drugs that interfere with other signaling pathways and cell-cycle progression. Important questions remain as how best to select each available strategy, how to sequence them and ultimately how to extend benefits to the largest number of patients in need.

Endocrine therapy for ER-positive/HER2-negative ...

7. Clinical Features and Prognosis Analysis of Hormone Receptor ...

  • Nov 29, 2022 · Breast cancer is hormone-dependent; endocrine therapy in patients with estrogen receptor (ER) and progesterone receptor (PR) positive breast ...

  • Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. From January 2010 to October 2016, 283 ER+/PR+/HER2-breast ...

Clinical Features and Prognosis Analysis of Hormone Receptor ...

8. Management of Hormone Receptor-Positive, HER2-Negative ...

  • Jun 3, 2020 · Approximately 70-80% of all breast cancers are HR positive, which includes expression of estrogen receptor (ER) and/or progesterone receptor (PR) ...

  • The majority of breast cancers are diagnosed at an early stage and are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Significant advances have been made in the management of early stage HR-positive, HER2-negative ...

Management of Hormone Receptor-Positive, HER2-Negative ...

9. Breast Cancer Hormone Receptor Status - Breastcancer.org

  • Feb 22, 2023 · ... estrogen receptor-negative and progesterone receptor-positive ... treat certain types of hormone receptor-positive, HER2-negative breast cancer.

  • Learn more about breast cancer hormone receptors and how to interpret your hormone receptor test results within your pathology report.

10. Poor prognosis of single hormone receptor- positive breast cancer

  • Mar 18, 2015 · ... ER-PR-HER2- tumors (triple-negative breast cancer) ... ER-PR + HER2- tumors received chemotherapy and endocrine therapy. Nevertheless, the ...

  • Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and progesterone receptor (PR) status. Generally, hormone receptor-positive (HR+) breast cancers have favorable prognosis. In order to understand the exact clinical characteristics and prognosis of single HR-positive breast cancer (ER + PR- tumors and ER-PR+ tumors), we compared these tumors to double HR+ tumors as well as HR- negative tumors (ER-PR-). We examined the clinical and biological features of 6,980 women with invasive ductal carcinoma, and these patients were stratified according to ER and PR expression as double HR+ (ER + PR+), single HR+ (ER + PR- and ER-PR+) and double HR-negative (HR-, ER-PR-) tumors. In this study, 571 (8.2%) cases were single HR+ tumors, of which 90 (1.3%) were ER-PR+ tumors and 481 (6.9%) were ER + PR- tumors. Our multivariate analysis showed that in patients without HER2 overexpression ER + PR- tumors were associated with an increased risk of recurrence and death compared with ER + PR+ tumors, with a hazard ratio of 2.12 for disease-free survival (DFS) and 4.79 for overall survival (OS). In patients without HER2 overexpression ER-PR+ tumors had increased risk of recurrence and death compared with ER + PR+ tumor, with a hazard ratio of 4.19 for DFS and 7.22 for OS. In contrast, in patients with HER2 overexpression, the difference in survival between single HR+ tumors and double HR+ HR- tumors was not statistically significant. In patients without HER2 overexpression the DFS and OS of ER + PR- and ER-PR+ tumors were not significantly different from those of ER-PR- tumors. We have identified clinically and biologically distinct features of single HR+ tumors (ER–PR+ and ER + PR–) through comparison with both ER + PR+ and ER-PR- tumors. These differences were only significant in HER2- tumors, not in HER2+ tumors. Single HR+ tumors without HER2 overexpression (ER + PR-HER2- or ER-PR + HER2-) were associated with poorer survival than ER + PR + HER2- tumors, and had comparable poor survival to ER-PR-HER2- tumors (triple-negative breast cancer).

Poor prognosis of single hormone receptor- positive breast cancer

11. Breast Cancer - Metastatic: Types of Treatment

  • Elacestrant is a treatment option for people with ER-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation. Elacestrant is only for ...

  • ON THIS PAGE: You will learn about the different types of treatments doctors use for people with metastatic breast cancer. Use the menu to see other pages.This section explains the types of treatments, also known as therapies, that are the standard of care for metastatic breast cancer. “Standard of care” means the best treatments known. Information in this section is based on medical standards of care for metastatic breast cancer in the United States. Treatment options can vary from one place to another.

Breast Cancer - Metastatic: Types of Treatment

12. Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation ...

  • This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 ...

  • On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5–9 of the TP53 gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3%) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, P = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation ...

13. Hormone Therapy for Breast Cancer Fact Sheet - NCI

  • Jul 12, 2022 · Most ER-positive breast cancers are also PR positive. ... positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.

  • Learn about the types of hormone therapy used to prevent and treat breast cancer (including antiestrogens, LH-RH agonists, aromatase inhibitors, and SERMs) and their possible side effects.

Hormone Therapy for Breast Cancer Fact Sheet - NCI

14. Is It Better to Be ER PR Positive or Negative? Breast Cancer Treatment

  • Estrogen receptor/progesterone receptor (ER/PR) positive breast cancers tend to grow more slowly than ER/PR negative cancers, and are more likely to respond ...

  • Estrogen receptor/progesterone receptor (ER/PR) positive breast cancers tend to grow more slowly than ER/PR negative cancers, and are more likely to respond to hormone therapy.

Is It Better to Be ER PR Positive or Negative? Breast Cancer Treatment

15. Tests on your breast cancer cells - Cancer Research UK

  • May 9, 2023 · They are called oestrogen receptor positive or ER positive (ER+) breast cancer. ... This is HER2 negative breast cancer; no cancer cells in the ...

  • These can help to find out the type of breast cancer you have and look for proteins (receptors) on the surface of breast cancer cells. They can also look at cancer genes (tumour profiling tests). 

Tests on your breast cancer cells - Cancer Research UK

16. How we treat HR-positive, HER2-negative early breast cancer

  • Jan 31, 2022 · On the other hand, is also relevant to highlight that PR negativity (in otherwise ER-positive tumors) can be considered as a marker of higher ...

  • We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×

17. Impact of low versus negative estrogen/progesterone receptor ...

  • Jul 11, 2022 · HER2-negative breast cancer with low ER/PR expression (1–10%) has a gene expression profile similar to TNBC; however, real-world treatment ...

  • Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression (1–10%) has a gene expression profile similar to TNBC; however, real-world treatment patterns, chemotherapy response, endocrine therapy benefit, and survival outcomes for the Low-ER group are not well known. 516 patients with stage I-III HER2-negative breast cancer and ER/PR expression ≤10% who were enrolled in a multisite prospective registry between 2011 and 2019 were categorized on the basis of ER/PR expression. TNBC (ER and PR < 1%) and Low-ER (ER and/or PR 1–10%) groups comprised 87.4% (n = 451) and 12.6% (n = 65) of patients, respectively. Demographic, clinical, and treatment characteristics, including prevalence of germline BRCA1/2 mutation, racial and ethnic distribution, and chemotherapy use were not different between TNBC and Low-ER groups. No difference was observed in recurrence-free survival (RFS) and overall survival (OS) between TNBC and Low-ER groups (3-year RFS 82.5% versus 82.4%, respectively, p = 0.728; 3-year OS 88.0% versus 83.4%, respectively, p = 0.632). Among 358 patients receiving neoadjuvant chemotherapy, rates of pathologic complete response were similar for TNBC and Low-ER groups (49.2% vs 51.3%, respectively, p = 0.808). The HER2-negative Low-ER group is often excluded from TNBC clinical trials assessing novel treatments (immunotherapy and antibody-drug conjugates), thus limiting efficacy data for newer effective therapies in this group. Given that HER2-negative Low-ER disease displays clinical characteristics and outcomes similar to TNBC, inclusion of this group in TNBC clinical trials is encouraged.

Impact of low versus negative estrogen/progesterone receptor ...

18. All About ER Positive, HER2 Negative Breast Cancer

  • Jun 7, 2016 · Cancerous cells may have none, one, or both receptors. Breast cancers that have estrogen receptors are called ER-positive (or ER+). Those with ...

  • About one in eight women in the United States will develop breast cancer, according to commonly used statistics. But other reports indicate that breast cancer rates are on the decline, likely because of improved recognition, prevention, and treatment. One advancement is the ability to identify different breast cancer types based on specific molecules found in tumors. […]

All About ER Positive, HER2 Negative Breast Cancer

FAQs

What is the best treatment for ER PR positive and HER2 negative breast cancer? ›

Group 1 (luminal A). This group includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.

Is chemo recommended for HER2 negative? ›

Chemotherapy. Keep in mind that not everyone with HER2-negative breast cancer needs chemotherapy. If you do, you will receive it before or after surgery, depending on factors like the size and extent of your cancer.

How do you treat hormone receptor positive and HER2 negative? ›

The treatment modalities generally employed for early stage HR-positive, HER2-negative breast cancer encompass a combination of definitive local therapy, which includes primary surgical management of the breast and axilla with or without adjuvant radiation, and adjuvant endocrine therapy with or without chemotherapy.

What is the best treatment for HER2 negative breast cancer? ›

Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose polymerase (PARP) from repairing cancer cells, so the cells die.

What is the prognosis of ER-positive and HER2 negative? ›

In general, ER-positive, HER2-negative breast cancers that are low grade, strongly ER and progesterone receptor (PR) positive, with low measures of proliferation have a good prognosis with endocrine treatment alone.

How serious is HER2 negative breast cancer? ›

The prognosis for HER2-negative breast cancer, if it's also hormone sensitive, can be very good, and life expectancy for cancers with this status can be slightly better than with HER2-positive cancer.

Is HER2 negative curable? ›

If your HER2-negative cancer is caught early, a surgeon may be able to remove it completely. Your doctor might also recommend radiation before or after surgery. Endocrine therapy. If your HER2-negative cancer is positive for hormone receptors, your doctor might suggest endocrine (hormone) therapy.

Is it better to be hormone receptor-positive or negative? ›

Hormone receptor-positive cancers tend to grow more slowly than those that are hormone receptor-negative. Women with hormone receptor-positive cancers tend to have a better outlook in the short-term, but these cancers can sometimes come back many years after treatment.

What oncotype score requires chemo? ›

For premenopausal women with either lymph node-negative or lymph node-positive breast cancer, if the Oncotype DX score is 26 or higher, a more aggressive treatment plan that includes both hormone therapy and chemotherapy is usually recommended [14,31-33].

What medication is used for HER2 negative? ›

Olaparib and talazoparib can be used to treat advanced or metastatic, HER2-negative breast cancer in women with a BRCA mutation who have already had chemotherapy. If the cancer is hormone receptor-positive, olaparib can also be used in women who have already received hormone therapy.

What drugs are used for HER2 negative chemotherapy? ›

Common chemotherapy drug combinations
Chemotherapy drug combinations for early and locally advanced breast cancer
HER2-negative breast cancers
TCHP†Docetaxel, carboplatin, trastuzumab and pertuzumab (Perjeta)
AC—>Paclitaxel (T) HDoxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab
20 more rows

Is ER positive and PR negative good or bad? ›

Estrogen receptor/progesterone receptor (ER/PR) positive breast cancers tend to grow more slowly than ER/PR negative cancers, and are more likely to respond to hormone therapy. Approximately two-thirds of breast cancers are ER and/or PR positive.

What is the prognosis for HER2-negative breast cancer? ›

Survival rates can vary based off of the subtype of breast cancer that you have. A publication from the American Cancer Society reports 5-year survival rates for HER2-negative breast cancers as: 92 percent for HER2-negative, HR-positive breast cancer. 77 percent for triple-negative breast cancer.

Can breast cancer change from HER2-positive to HER2-negative? ›

Your HER2 status can change as your cancer grows or returns. That is, HER2-positive cancer can become HER2-negative and vice versa. You and your doctor may decide to retest for HER2 over time or if your cancer comes back after treatment.

Does HER2-negative breast cancer recur? ›

ER+/PR+ and HER2 patients have higher risk of recurrence later than 5 years, especially in patients with high ER titer and low nuclear grade. Larger and node-positive tumors had higher risk of early recurrence.

Is HER2-positive breast cancer more aggressive than HER2 negative? ›

Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein.

What is the treatment for HER2 negative hormone therapy? ›

HER2-negative breast cancer that's HR-positive can be treated with hormone therapy. This blocks the actions of hormones, stopping the cancer from growing. aromatase inhibitors: lower estrogen levels in the body, and include: anastrozole (Arimidex)

What is targeted therapy for ER PR positive breast cancer? ›

Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) are drugs that block proteins in the cell called cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. Blocking these proteins in hormone receptor-positive breast cancer cells helps stop the cells from dividing. This can slow cancer growth.

What is the treatment for ER PR positive breast cancer? ›

Hormone receptor-positive (or hormone-positive) breast cancer cells have either estrogen (ER) or progesterone (PR) receptors or both. These breast cancers can be treated with hormone therapy drugs that lower estrogen levels or block estrogen receptors.

References

Top Articles
Latest Posts
Article information

Author: Merrill Bechtelar CPA

Last Updated: 11/01/2024

Views: 6356

Rating: 5 / 5 (50 voted)

Reviews: 89% of readers found this page helpful

Author information

Name: Merrill Bechtelar CPA

Birthday: 1996-05-19

Address: Apt. 114 873 White Lodge, Libbyfurt, CA 93006

Phone: +5983010455207

Job: Legacy Representative

Hobby: Blacksmithing, Urban exploration, Sudoku, Slacklining, Creative writing, Community, Letterboxing

Introduction: My name is Merrill Bechtelar CPA, I am a clean, agreeable, glorious, magnificent, witty, enchanting, comfortable person who loves writing and wants to share my knowledge and understanding with you.